egnite has launched the CardioCare Research Suite, an advanced component of its flagship platform, aimed at enhancing patient identification processes for cardiovascular clinical trials.
This tool is designed to support research teams in streamlining patient selection, thereby accelerating the pace of trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The CardioCare Research Suite has been integrated into ten clinical trials focusing on structural heart and heart failure treatments.
These trials include ALT-FLOW II, AIM-HIGHer, APOLLO, CLASP IIF, ARTIST, CLASP II TR, CORCINCH-HF, ENCIRCLE, EMPOWER and PROGRESS.
The suite leverages artificial intelligence (AI) and natural language processing to analyse structured as well as unstructured data from hospital records, enhancing the identification and recruitment of suitable patients for clinical trials.
This helps expand access to new treatments while minimising the operational load on research teams.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Research Suite has already demonstrated significant impact in its early adoption phase. Hospitals have reported that over half of the patients identified through the platform had not previously been considered by the principal investigator or relevant specialists.
Additionally, between 25% and 50% of patient consents were obtained directly as a result of the CardioCare platform’s capabilities.
Trial coordinators have experienced a marked reduction in the time required to identify potential trial participants.
The platform’s precise and patient-focused outreach is particularly beneficial in navigating the complexities of evolving eligibility criteria for clinical trials.
egnite chief operating officer Kahla Verhoef said: “Since our inception, ambitious programmes have expressed a desire to leverage the CardioCare platform to move from passive intake to proactive identification of clinical trial patients.
“The Research Suite is a direct response to that need, empowering research teams to efficiently surface eligible patients from complex data, align with evolving trial criteria, and engage physicians with precision and confidence.”
egnite’s CardioCare Research Suite is now accessible to all partnering hospitals already utilising the CardioCare platform.
Its ability to process and analyse AI across diverse data sets equips research teams with a tool to expedite enrollment and foster clinical innovation.
